Sun Pharma Q4 net declines 14% to Rs 1,223 cr, warns of fall in FY18 sales

Increased competition, pricing pressure, regulatory challenges continue to impact sales in US

Sun Pharmaceutical Industries has guided for a possible single-digit decline in sales, owing to regulatory challenges. This comes after it posted a 14 per cent decline in consolidated net profit for the Q4FY17.

 
Net profit for the quarter dropped to Rs 1,223 crore, against Rs 1,416 crore in the year-ago period. Total revenue, including other income, fell 6.3 per cent to Rs 7361 crore on a year-on-year (y-o-y) basis. Increased competition, pricing pressure and regulatory challenges continue to impact sales in the US market. Sales from this market declined 34 per cent on a y-o-y basis. Sun Pharma’s subsidiary, Taro,